Tamoxifen has been shown to significantly reduce the risk of breast cancer recurrence and mortality. It also decreases the likelihood of developing new cancers in the contralateral breast. Moreover, tamoxifen is relatively well-tolerated and its benefits in breast cancer prevention extend for many years even after discontinuation of the therapy.
